Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6LJN

Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P15

6LJN の概要
エントリーDOI10.2210/pdb6ljn/pdb
分子名称NAD-dependent protein deacylase sirtuin-5, mitochondrial, ACE-HIS-PHE-SER-SLL, ZINC ION, ... (5 entities in total)
機能のキーワードsirt5, inhibitor, hydrolase
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数2
化学式量合計30453.96
構造登録者
Chen, Q.,Yu, Y. (登録日: 2019-12-17, 公開日: 2020-10-28, 最終更新日: 2023-11-29)
主引用文献Yang, L.L.,Wang, H.L.,Yan, Y.H.,Liu, S.,Yu, Z.J.,Huang, M.Y.,Luo, Y.,Zheng, X.,Yu, Y.,Li, G.B.
Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.
Eur.J.Med.Chem., 192:112201-112201, 2020
Cited by
PubMed Abstract: Sirtuins (SIRTs) are NAD-dependent lysine deacylases, regulating many important biological processes such as metabolism and stress responses. SIRT inhibitors may provide potential benefits against SIRT-driven human diseases. Development of efficient assay platforms based on fluorogenic substrates will facilitate the discovery of high-quality SIRT inhibitors. We here report 16 new fluorogenic peptide substrates (P1-P16) designed with structurally diverse tetrapeptides and acyl modifications. Tests of P1-P16 against SIRT isoforms identified several sensitive substrates for SIRT1, SIRT2, SIRT3 and SIRT5, which manifested lower K values and higher catalytic efficiency, and particularly had less signal interference in inhibitor screening compared with our previously reported internally quenched fluorescent substrates. Co-crystallization of sensitive substrates P13 and P15 with SIRT5 revealed an unexpected binding mode, involving interactions with residues from active site bordering surfaces, different from that observed for other peptides derived from natural protein substrates. By using SIRT5 sensitive substrates, we found that TW-37, a Bcl-2 inhibitor, displayed low micromolar inhibition to SIRT5, which was further validated by isothermal titration calorimetry analyses, offering a new point to develop dual-action SIRT5/Bcl-2 inhibitors against cancers. This work provides assay platform and structural basis for developing new substrates and inhibitors targeting human SIRTs.
PubMed: 32163813
DOI: 10.1016/j.ejmech.2020.112201
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.8 Å)
構造検証レポート
Validation report summary of 6ljn
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon